Antibodies that specifically bind to 4-1BB and antigen-binding fragments thereof

Abstract

The present invention relates to an antibody and an antigen-binding fragment thereof that specifically bind to 4-1BB. The antibody and the antigen-binding fragment thereof that specifically bind to 4-1BB have high specificity, and after the antibody and the antigen-binding fragment thereof bind to an antigen, they can enhance the immune killing function of T cells, induce the activation of immune cells, and promote the secretion of cytokines, thereby significantly inhibiting tumor growth in vivo.

Description

[Technical Field]

[0001] The present invention relates to the field of antibody and antibody humanization modification research, and in particular, the present invention relates to an antibody and an antigen-binding fragment thereof capable of specifically binding to 4-1BB. [Background technology]

[0002] Monoclonal antibodies are highly target-specific antibodies that act only on a single antigen epitope and are widely used to treat many diseases, such as cancer, inflammation, autoimmune diseases, and infectious diseases. Such target-specific drugs are particularly important after cancer chemotherapy has become ineffective.

[0003] 4-1BB is a costimulatory molecule belonging to the TNFRSF family. It was discovered in the late 1980s during T cytokine screening by stimulating mouse helper T cells and cytotoxic T cells with concanavalin A. Human 4-1BBL was first isolated in 1994 from CD4+ T lymphocytes activated by a direct expression clone. 4-1BBL is primarily expressed on dendritic cells, B cells, or macrophages. Existing studies have demonstrated that the TNFSF-TNFRSF ligand-receptor (e.g., CD40-CD40L, CD27-CD70, or OX40-OX40L) signaling pathway can regulate many important processes in vivo, such as cell development and death, and the induction of cytokines and chemokines. Growing evidence suggests that TNFRSF and TNFSF members are involved in inflammation and pathology in various diseases, including cancer. In immunotherapy, effective immune responses require two types of signals to fully activate T cells and other immune cells. The first type of signal, the antigen-specific signal, is generated by the interaction of lymphocyte receptors with specific peptides bound by major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs). The second type, the antigen-nonspecific costimulatory signal, is provided by the interaction between T cells and costimulatory molecules expressed on APCs.

[0004] Therefore, immunotherapeutic techniques directed against TNFSF and TNFRSF ligand-receptor interactions have great potential in the treatment of cancer. There is still a need in this field to develop more effective antibodies that specifically bind to 4-1BB. Summary of the Invention

[0005] A first aspect of the present invention relates to an isolated anti-human 4-1BB antibody or antigen-binding fragment thereof, or a variant or derivative thereof, wherein the antibody or antigen-binding fragment thereof comprises three complementarity-determining regions (LCDRs) of a light chain variable region as shown in SEQ ID NO. 7 and three complementarity-determining regions (HCDRs) of a heavy chain variable region as shown in SEQ ID NO. 8.

[0006] The antibody or antigen-binding fragment thereof comprises a light chain variable region and / or a heavy chain variable region, wherein the light chain variable region comprises an amino acid sequence such as LCDR1 shown in SEQ ID No. 1, an amino acid sequence such as LCDR2 shown in SEQ ID No. 2, or an amino acid sequence such as LCDR3 shown in SEQ ID No. 3, and / or the heavy chain variable region comprises an amino acid sequence such as HCDR1 shown in SEQ ID No. 4, an amino acid sequence such as HCDR2 shown in SEQ ID No. 5, or an amino acid sequence such as HCDR3 shown in SEQ ID No. 6.

[0007] The amino acid sequences of the CDRs of the light chain variable region or heavy chain variable region shown are variant sequences that have at least 70% identity, for example at least 75%, 80%, 85%, 90%, 95% or more identity, to the sequences shown in SEQ ID Nos. 1-3 or 4-6, respectively, and retain the biological activity of the corresponding parent sequences; or the amino acid sequences of the CDRs of the light chain variable region or heavy chain variable region shown are variant sequences that have been modified by deleting, substituting and / or adding one or more amino acid residues, for example one, two, three or more, to the sequences shown in SEQ ID Nos. 1-3 or 4-6, respectively, and retain the biological activity of the corresponding parent sequences.

[0008] In some embodiments, the variant is selected from a chimeric antibody, a humanized antibody, or a fully humanized antibody.

[0009] In some embodiments, the antibody heavy chain constant region sequence is selected from the constant region sequence of any of human IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, and / or the antibody light chain constant region sequence is selected from the κ chain or λ chain. Preferably, the heavy chain constant region sequence is selected from the constant region sequence of IgG1 or IgG4, and / or the light chain constant region sequence is selected from the constant region sequence of the κ light chain.

[0010] In some embodiments, the amino acid sequence of the light chain variable region of the 4-1BB chimeric antibody and functional fragments thereof is set forth in SEQ ID NO. 7, or has at least 70% identity, e.g., at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, to the sequence set forth in SEQ ID NO. 7, and retains the biological activity of the corresponding parent sequence, or is a variant sequence obtained by deleting, substituting, and / or adding one or more, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more, amino acid residues from the sequence set forth in SEQ ID NO. 7, and retaining the biological activity of the corresponding parent sequence; and / or the amino acid sequence of the heavy chain variable region is set forth in SEQ ID NO. 8, or has at least 70% identity, e.g., at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity, to the sequence set forth in SEQ ID NO. 7, and retains the biological activity of the corresponding parent sequence. or a variant sequence obtained by deleting, substituting and / or adding one or more amino acid residues, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more, to the sequence set forth in SEQ ID NO. 8, and retaining the biological activity of the corresponding parent sequence.

[0011] In some embodiments, the 4-1BB chimeric antibodies and functional fragments thereof comprises a light chain variable region and a heavy chain variable region , where: (a) the light chain variable region has an amino acid sequence selected from the group consisting of SEQ ID NOs. 13-20; and / or The heavy chain variable region has an amino acid sequence selected from SEQ ID NOs. 21-31; (b) the light chain variable region has the amino acid sequence set forth in SEQ ID NO. 11; and / or The heavy chain variable region has an amino acid sequence selected from SEQ ID NOs. 21-31; (c) the light chain variable region has an amino acid sequence selected from the group consisting of SEQ ID NOs. 13-20; and / or The heavy chain variable region has the amino acid sequence shown in SEQ ID NO.12.

[0012] Preferably, the light chain variable region has the amino acid sequence shown in SEQ ID NO.11; and / or the heavy chain variable region has the amino acid sequence shown in SEQ ID NO.12.

[0013] In some embodiments, the antigen-binding fragment is one or more selected from F(ab')2, Fab', Fab, Fd, Fv, scFv, bispecific antibody, camel antibody, CDR, and minimal antibody recognition unit (dAb), and preferably the antigen-binding fragment is Fab, F(ab')2, or scFv.

[0014] A second aspect of the present invention relates to an isolated nucleic acid molecule selected from: (1) DNA or RNA encoding the anti-human 4-1BB antibody according to the first aspect, its antigen-binding fragment, its mutant, or its derivative; (2) A nucleic acid that is completely complementary to the DNA or RNA defined in (1).

[0015] A third aspect of the present invention relates to a vector comprising operatively ligated nucleic acid molecules according to the second aspect, preferably said vector being an expression vector.

[0016] A fourth aspect of the present invention relates to a host cell comprising a nucleic acid molecule according to the second aspect or a vector according to the third aspect.

[0017] A fifth aspect of the present invention relates to a composition comprising an anti-human 4-1BB antibody, an antigen-binding fragment thereof, a variant thereof or a derivative thereof according to the first aspect, a nucleic acid molecule according to the second aspect, a vector according to the third aspect or a host cell according to the fourth aspect, and a pharmaceutically acceptable excipient.

[0018] A sixth aspect of the present invention relates to a method for producing an anti-human 4-1BB antibody, its antigen-binding fragment, variant or derivative thereof according to the first aspect, said method comprising expressing a host cell according to the fourth aspect under culture conditions suitable for expression of said anti-human 4-1BB antibody, its antigen-binding fragment or variant thereof, optionally comprising isolating and purifying the obtained product, and optionally comprising conjugating the obtained product to a diagnostic and / or therapeutic agent as described above.

[0019] A seventh aspect of the present invention relates to use of the anti-human 4-1BB antibody according to the first aspect, its antigen-binding fragment, its variant or derivative thereof, the nucleic acid molecule according to the second aspect, the vector according to the third aspect or the host cell according to the fourth aspect in the manufacture of a medicament for preventing and / or treating an autoimmune disease, an immune response to a transplant, an allergic reaction, an infectious disease, a neurodegenerative disease and a tumor.

[0020] An eighth aspect of the present invention relates to use of the anti-human 4-1BB antibody according to the first aspect, its antigen-binding fragment, variant or derivative thereof, the nucleic acid molecule according to the second aspect, the vector according to the third aspect, or the host cell according to the fourth aspect in a medicament for preventing and / or treating a 4-1BB-mediated disease or condition, wherein the disease or condition is preferably a tumor. More preferably, the tumor is one or more selected from leukemia, lymphoma, myeloma, brain tumor, head and neck squamous cell carcinoma, non-small cell lung cancer, nasopharyngeal carcinoma, esophageal cancer, gastric cancer, pancreatic adenocarcinoma, gallbladder cancer, liver cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, bladder cancer, renal cell carcinoma, and melanoma.

[0021] A ninth aspect of the present invention relates to a method for preventing and / or treating a tumor, comprising the step of administering to a subject in need thereof an anti-human 4-1BB antibody, antigen-binding fragment thereof, variant thereof or derivative thereof according to the first aspect, a nucleic acid molecule according to the second aspect, a vector according to the third aspect or a host cell according to the fourth aspect.

[0022] In some embodiments, the tumor is one or more selected from leukemia, lymphoma, myeloma, brain tumor, squamous cell carcinoma of the head and neck, non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, esophageal cancer, gastric cancer, pancreatic adenocarcinoma, gallbladder cancer, liver cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, bladder cancer, urothelial carcinoma, renal cell carcinoma, osteosarcoma, melanoma, and Merkel cell carcinoma. Preferably, the tumor is one or more selected from lymphoma, myeloma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, esophageal cancer, gastric cancer, liver cancer, colorectal cancer, breast cancer, cervical cancer, endometrial cancer, prostate cancer, urothelial carcinoma, renal cell carcinoma, osteosarcoma, melanoma, and Merkel cell carcinoma. More preferably, the tumor is one or more selected from lymphoma, head and neck squamous cell carcinoma, non-small cell lung cancer, gastric cancer, liver cancer, colorectal cancer, cervical cancer, urothelial carcinoma, renal cell carcinoma, melanoma, and Merkel cell carcinoma.

[0023] In some embodiments, the subject is selected from mammals, including, but not limited to, humans and / or other primates, including commercially relevant mammals such as cows, pigs, horses, goats, cats, dogs, mice, and / or rats.

[0024] In some embodiments, the anti-human 4-1BB antibody, its antigen-binding fragment, its variant or derivative, nucleic acid molecule, vector or host cell of the present invention is used by a conventional application method in the art, for example, parenteral route, intravenous administration.

[0025] The anti-4-1BB monoclonal antibody of the present invention has high specificity, good stability, strong T cell function-regulating activity, and favorable pharmacokinetic properties, and can significantly inhibit tumor growth in vivo. Furthermore, the anti-4-1BB monoclonal antibody of the present invention has stronger blocking activity against 4-1BB / 4-1BBL than the urelumab monoclonal antibody.

[0026] In order to more clearly explain the specific embodiments of the present invention or the technical solutions in the prior art, the drawings that need to be used in the description of the specific embodiments or the prior art will be briefly introduced below. Please note that the drawings in the following description only represent some embodiments of the present invention. Those skilled in the art can obtain other drawings from these drawings without any creative work. [Brief explanation of the drawings]

[0027] [Figure 1] FIG. 1A shows the binding activity of the anti-human 4-1BB chimeric monoclonal antibody sequence to 4-1BB, and FIG. 1B shows the agonistic activity of the anti-human 4-1BB chimeric monoclonal antibody sequence to 4-1BB. [Figure 2] 1 shows the binding activity of anti-human 4-1BB chimeric monoclonal antibody mAb-33-83 to 4-1BB. [Figure 3]FIG. 3A shows the species specificity of the anti-human 4-1BB chimeric monoclonal antibody mAb-33-83, and FIG. 3B shows the binding specificity of the anti-human 4-1BB chimeric monoclonal antibody mAb-33-83. [Figure 4] 1 shows the blocking activity of anti-human 4-1BB chimeric monoclonal antibody mAb-33-83 on 4-1BB / 4-1BBL binding. [Figure 5] 1 shows the antitumor effect of anti-human 4-1BB chimeric monoclonal antibody mAb-33-83 in a gene knock-in mouse homologous tumor model. [Figure 6] 1 shows the binding activity of anti-human 4-1BB humanized monoclonal antibody BH3145b to 4-1BB. [Figure 7] 1 shows the blocking activity of anti-human 4-1BB humanized monoclonal antibody BH3145b on 4-1BB / 4-1BBL binding. DETAILED DESCRIPTION OF THE INVENTION

[0028] definition The term human "4-1BB", i.e., CD137, belongs to the tumor necrosis factor receptor superfamily member (TNFRSF9), is expressed primarily on activated T cells, and is a T cell costimulatory molecule, the ligand of which is 4-1BBL.

[0029] As used herein, the terms "anti-4-1BB antibody," "anti-4-1BB," "4-1BB antibody," "anti-4-1BB monoclonal antibody," or "antibody that binds to 4-1BB" refer to an antibody that can bind to a 4-1BB protein or a fragment thereof with sufficient affinity. In some embodiments, the anti-4-1BB antibody binds to a conserved 4-1BB epitope in a heterologous 4-1BB.

[0030] The term "antibody" refers to an immunoglobulin molecule or a fragment of an immunoglobulin molecule capable of binding to an epitope of an antigen. Naturally occurring antibodies typically comprise a tetramer and are usually composed of at least two heavy (H) chains and at least two light (L) chains. Immunoglobulins include the isotypes IgG (IgG1, IgG2, IgG3, and IgG4 subclasses), IgA (IgA1 and IgA2 subclasses), IgM, and IgE, whose corresponding heavy chains are μ, δ, γ, α, and ε chains, respectively. Light chains are divided into κ and λ chains depending on the constant region.

[0031] As used herein, the term "antibody" is used in the broadest sense to refer to a protein that contains an antigen-binding site and includes natural and artificial antibodies of various structures, including, but not limited to, complete antibodies and antigen-binding fragments of antibodies.

[0032] A "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to its antigen. Each heavy chain of an antibody is composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region (abbreviated herein as CH), and the heavy chain constant region is usually composed of three domains (CH1, CH2, and CH3). Each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region (abbreviated herein as CL). The heavy and light chain variable regions are typically responsible for antigen recognition, while the heavy and light chain constant regions can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells), Fc receptors, and the first component (C1q) of the classical complement system. The heavy and light chain variable regions contain binding regions that interact with antigens. The VH and VL regions are further divided into hypervariable regions (HVRs) called "complementarity-determining regions (CDRs)," with more conserved regions called "framework regions" (FRs) intervening between them. Each VH and VL is composed of three CDR domains and four FR domains, arranged in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 from the amino terminus to the carboxyl terminus.

[0033] The terms "complementarity determining region" or "CDR region" or "CDR" (which may be used interchangeably herein with hypervariable region "HVR") refer to the regions of an antibody variable domain that form highly variable sequence and structurally determined loops ("hypervariable loops") and / or contain antigen contact residues ("antigen contact points"). The CDRs are primarily responsible for binding to an epitope of an antigen. Herein, the three CDRs of the heavy chain are referred to as HCDR1, HCDR2, and HCDR3, and the three CDRs of the light chain are referred to as LCDR1, LCDR2, and LCDR3.

[0034] It should be noted that the CDR boundaries of the variable regions of the same antibody obtained based on different numbering schemes may be different. That is, the CDR sequences of the variable regions of the same antibody defined by different numbering schemes will be different. Therefore, when antibodies are defined using specific CDR sequences defined in the present invention, the scope of the antibody also includes antibodies whose variable region sequences contain the specific CDR sequences, but whose so-called CDR boundaries differ from the specific CDR boundaries defined in the present invention by applying a different scheme (e.g., a rule or combination of different numbering schemes).

[0035] The terms "monoclonal antibody," "monoclonal antibody," or "monoclonal antibody composition" refer to an antibody obtained from a substantially homogeneous antibody population as a preparation of antibody molecules of a single molecular composition, i.e., a population comprising individual antibodies that are identical except for minor, possibly naturally occurring mutations. A typical monoclonal antibody composition exhibits a single binding specificity and affinity for a particular epitope. In some embodiments, a monoclonal antibody may be composed of two or more Fab domains, thereby enhancing specificity for two or more targets. The terms "monoclonal antibody" or "monoclonal antibody composition" are not limited to any particular method of production (e.g., recombinant, transgenic, hybridoma, etc.).

[0036] The terms "dual antibody," "dual functional antibody," "bispecific antibody," or "BsAb" refer to an antibody that has two different antigen-binding sites and can simultaneously bind to two target antigens, exerting its antibody targeting properties while also mediating the action of another specialized functional effector molecule. The specialized functional effector molecule mediated may be a toxin, enzyme, cytokine, radionuclide, etc., and the two antigen-binding arms of the bispecific antibody may each be derived from Fab, Fv, ScFv, dSFv, etc.

[0037] The term "polyclonal antibody" refers to a preparation of different antibodies directed against different antigenic determinants ("epitopes").

[0038] The term "antigen-binding fragment of an antibody" refers to a fragment, portion, region, or domain of an antibody (which may be obtained, for example, by truncation, recombinantly, synthetically, etc.) that is capable of binding to an epitope. An antigen-binding fragment may comprise one, two, three, four, five, or all six CDR domains of such an antibody, and may exhibit different specificities, affinities, or selectivities while still being capable of binding to the epitope. Preferably, the antigen-binding fragment comprises all six CDR domains of the antibody. An antigen-binding fragment of an antibody may be part of or comprises a single polypeptide chain (e.g., an scFv), or may be part of or comprises two or more polypeptide chains (each having an amino terminus and a carboxyl terminus) (e.g., a bibody, an Fab fragment, an F(ab')2 fragment, etc.).

[0039] Examples of antigen-binding fragments encompassed by the present invention include: (a) Fab' or Fab fragments, which are monovalent fragments consisting of the VL, VH, CL, and CH1 domains; (b) F(ab')2 fragments, which are bivalent fragments comprising two Fab fragments linked by a disulfide bond at the hinge domain; (c) Fd fragments, which consist of the VH and CH1 domains; (d) Fv fragments, which consist of the VL and VH domains of one arm of an antibody; (e) single-chain antibodies (single-chain Fv, scFv), which are recombinant proteins in which antibody VH and VL are linked by a connecting peptide segment using genetic engineering techniques; (f) dAb fragments (Ward et al., Nature, 341, 544-546 (1989)), which are essentially composed of the VH domain and are also called domain antibodies (Holt et al., Trends Biotechnol., 2i(ll): 484-90); (g) camelid or nanoantibodies (Revets et al., Expert Opin Biol Ther., 5(l): 111-24) and (h) isolated complementarity determining regions (CDRs).

[0040] The term "chimeric antibody" refers to an antibody in which a portion of the heavy and / or light chain is identical or homologous to the corresponding sequence of an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence of an antibody derived from another species or belonging to another antibody class or subclass, and to fragments of such an antibody, so long as the desired biological activity is exhibited. The present invention provides variable region antigen-binding sequences derived from human antibodies. Therefore, the chimeric antibodies primarily focused on herein include antibodies having one or more human antigen-binding sequences (e.g., CDRs) and containing one or more sequences derived from a non-human antibody, such as FR or C region sequences. Note that the chimeric antibody described herein refers to an antibody containing human variable region antigen-binding sequences of one antibody class or subclass and other sequences, such as FR or C region sequences, derived from another antibody class or subclass.

[0041] The term "humanized antibody" refers to an antibody in which CDR sequences from another mammalian species, such as a mouse species, have been grafted onto human framework sequences, in which additional framework region modifications can be made.

[0042] The term "human antibody" or "fully human antibody" ("humAb" or "HuMab") includes antibodies having variable and constant regions derived from human species-based immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human species-based immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro, or during gene rearrangement, or by somatic mutation in vivo).

[0043] Mutant antibodies are also within the scope of the present invention. Therefore, variants of the sequences listed herein are also within the scope of the present invention. Other variants of antibody sequences with improved affinity can be obtained using methods known in the art, and these variants are also within the scope of the present invention. For example, amino acid substitutions can be used to obtain antibodies with further improved affinity. Alternatively, codon optimization of nucleotide sequences can be used to improve the translation efficiency of expression systems for antibody production. The sequences of such variant antibodies share 70% or more (e.g., 80%, 85%, 90%, 95%, 97%, 98%, 99% or more) sequence identity with the sequences listed herein. Such sequence identity is calculated based on the full length of the reference sequence (i.e., the sequences listed herein).

[0044] The amino acid residues in the regions of the present invention are numbered according to IMGT®, the international ImMunoGeneTics information system®, or Kabat, EA, Wu, TT, Perry, HM, Gottesmann, KS & Foeller, C., (1991), Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication No. 91-3242, U.S. Department of Health and Human Services; Chothia, C. & Lesk, AM, (1987), Canonical Structures For The Hypervariable Domains Of Immunoglobulins., J. Mol. Biol., 196, 901-917. Unless otherwise specified, the amino acid residues in the present invention are numbered according to the Kabat EU index numbering system.

[0045] An antibody or antigen-binding fragment thereof "specifically" binds to a region of another molecule (i.e., an epitope) if it reacts or binds to that epitope more frequently, more rapidly, with a longer duration, and / or with greater affinity than it does to other epitopes. In some embodiments, the antibodies or antigen-binding fragments thereof of the invention bind to at least 10 -7 M, e.g. 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 The antibody or antigen-binding fragment thereof binds to human 4-1BB with an affinity of M or greater. Preferably, the antibody or antigen-binding fragment thereof binds under physiological conditions (e.g., in vivo). Thus, specifically binding to 4-1BB refers to the antibody or antigen-binding fragment thereof's ability to bind to 4-1BB with the above specificity and / or under such conditions. Suitable methods for determining such binding are known in the art.

[0046] In the context of antibody binding to a designated antigen, the term "binding" typically refers to binding of approximately 10 -6M or less, which KD is at least 10-fold, e.g., at least 100-fold, or at least 1,000-fold lower than the affinity of the antibody's binding to a nonspecific antigen other than the designated antigen or a closely related antigen (e.g., BSA, casein).

[0047] As used herein, the term "kd" (sec-1 or 1 / s) refers to the dissociation rate constant of a particular antibody-antigen interaction. Said value is also referred to as the koff value.

[0048] As used herein, the term "ka" (M-1 x sec-1 or 1 / Msec) refers to the association rate constant of a particular antibody-antigen interaction.

[0049] As used herein, the term "KD" (M) refers to the dissociation equilibrium constant of a particular antibody-antigen interaction and is obtained by dividing kd by ka.

[0050] As used herein, the term "K" (M-1 or 1 / M) refers to the binding equilibrium constant of a particular antibody-antigen interaction and is obtained by dividing k by k.

[0051] In some embodiments, the antibodies or antigen-binding fragments thereof of the present invention may be humanized such that only a portion of the CDRs (i.e., the subgroup of CDR residues necessary for binding, called SDRs) are combined. Based on previous studies, such as those described in Gonzales, N.R. et al. (2004), SDR Grafting of a Murine Antibody Using Multiple Human GermLine Templates to Minimize Its Immunogenicity, Mol. Immunol., 41:863-872, CDR residues that do not contact the relevant epitope and are not located in the SDRs can be identified from Kabat CDR regions located outside the Chothia hypervariable loops (e.g., residues H60-H65 in CDR H2 are typically dispensable) (see Kabat et al. (1992), Sequences of Proteins of Immunological Interest, National Institutes of Health, Publication No. 91-3242; Chothia, C. et al. (1987), Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol., 196:901-917). In such humanized antibodies, at positions where one or more donor CDR residues are absent or where the entire donor CDR is omitted, the amino acid occupying this position may be the amino acid occupying the corresponding position (numbered according to Kabat) in the recipient antibody sequence. Such substitutions are potentially advantageous in reducing the number of murine amino acids in the humanized antibody, thereby reducing potential immunogenicity. However, substitutions may also result in changes in affinity, and it is desirable to avoid significant decreases in affinity. The substitution positions within the CDRs and the amino acids to be substituted can also be selected empirically.

[0052] The fact that changing a single amino acid in a CDR residue results in loss of functional binding (Rudikoff, S. et al. (1982), Single Amino Acid Substitution Altering Antigen-binding Specificity, Proc. Natl. Acad. Sci. (USA)) 79(6):1979-1983) can be used to systematically identify alternative functional CDR sequences. In a preferred method for obtaining such mutant CDRs, the polynucleotide encoding the CDR is mutated (e.g., by random or site-directed mutagenesis) to generate a CDR with a substituted amino acid residue. The substitution score of this substituted BLOSUM62.iij can be determined by comparing the identity of the relevant residue in the original (functional) CDR sequence with that of the substituted (non-functional) mutant CDR sequence. The BLOSUM system provides amino acid substitution matrices created by analyzing sequence databases and used to compare reliability (Eddy, SR, (2004), Where Did The BLOSUM62 Alignment Score Matrix Come From?, Nature Biotech., 22(8):1035-1036; Henikoff, JG, (1992), Amino acid substitution matrices from protein blocks), Proc. Natl. Acad. Sci. (USA), 89:10915-10919; Karlin, S. et al., (1990), Methods For Assessing The Statistical Significance Of Molecular Sequence Features By Using General Scoring Schemes), PNAS, 87:2264-2268; Altschul, SF, (1991), Amino Acid Substitution Matrices From An Information Theoretic Perspective, J. Mol. Biol., 219, 555-565.Currently, the most advanced BLOSUM database is the BLOSUM62 database (BLOSUM62.iij). Table 1 shows the BLOSUM62.iij substitution scores (the higher the score, the more conservative the substitution and the more likely it is that the substitution will not affect function). For example, if the resulting antigen-binding fragment containing the CDR cannot bind to 4-1BB, the BLOSUM62.iij substitution score is considered not sufficiently conservative, and new candidate substitutions with higher substitution scores are selected and generated. Thus, for example, if the original residue is glutamic acid (E) and the non-functional replacement residue is histidine (H), the BLOSUM62.iij substitution score is 0, and more conservative changes (e.g., aspartic acid, asparagine, glutamine, or lysine) are preferred.

[0053] [Table 1]

[0054] Thus, the present invention contemplates the use of random mutagenesis in identifying improved CDRs. In the context of the present invention, conservative substitutions may be defined by substitutions within one or more of the amino acid categories in the following three tables:

[0055] Types of amino acid residues to be conservatively substituted: [Table 2]

[0056] Alternative conservative amino acid residue substitution types: [Table 3]

[0057] Classification of physical and functional alternatives of amino acid residues: [Table 4]

[0058] More conservative substitution groups include: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

[0059] In some embodiments, the hydrophilic amino acids are selected from Arg, Asn, Asp, Gln, Glu, His, Tyr, and Lys.

[0060] Additionally, additional amino acid groups can be generated using the principles described, for example, in Creighton, (1984), Proteins: Structure and Molecular Properties, WH Freeman and Company.

[0061] Thus, the sequences of the CDR variants of the included antibodies or antigen-binding fragments thereof can differ from the sequences of the CDRs of the parent antibody by substitutions, such as by substitutions of 4, 3, 2, or 1 amino acid residue. According to embodiments of the invention, amino acids in the CDR regions may be substituted with conservative substitutions, as defined in the three tables above.

[0062] "Homology" or "sequence identity" refers to the percentage of identical residues between a polynucleotide or polypeptide sequence variant and a non-variant sequence after aligning the sequences and introducing gaps. In specific embodiments, polynucleotide and polypeptide variants have at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% polynucleotide or polypeptide homology with the polynucleotides or polypeptides described herein.

[0063] Such variant polypeptide sequences have 70% or more (i.e., 80%, 85%, 90%, 95%, 97%, 98%, 99% or more) sequence identity to the sequences set forth herein. In other embodiments, the present invention provides polypeptide fragments comprising contiguous stretches of various lengths of the amino acid sequences disclosed herein. For example, where applicable, the peptide sequences provided herein include at least about 5, 10, 15, 20, 30, 40, 50, 75, 100, 150, or more consecutive peptides of one or more of the sequences disclosed herein, as well as all peptides of intermediate lengths therebetween.

[0064] The term "treatment" refers to ameliorating, alleviating, attenuating, or reversing the progression or severity of a disease or condition, or ameliorating, alleviating, attenuating, or reversing one or more symptoms or side effects of such a disease or condition. In the present invention, "treatment" also refers to an approach for obtaining a beneficial or promising clinical result, where "beneficial or promising clinical result" includes, but is not limited to, alleviation of symptoms, reduction in the condition or extent of disease, stabilized (i.e., not worsening) state of the disease or condition, delaying or alleviating the progression of the condition of the disease or condition, improvement or palliation of the condition of the disease or condition, and remission of the disease or condition, whether partial or total, detectable or undetectable.

[0065] The term "prevention" refers to preventing or inhibiting the development of at least one symptom of a disease or condition by administering the antibodies and functional fragments thereof of the present invention. This term further includes treating a subject in remission to prevent or inhibit recurrence.

[0066] The antibodies of the present invention may be monoclonal antibodies produced by recombinant DNA.

[0067] The antibody of the present invention may have any isotype. The choice of isotype is usually determined by the desired effector function (e.g., ADCC induction). Exemplary isotypes are IgG1, IgG2, IgG3, and IgG4. Either the κ or λ human light chain constant region can be used. If necessary, the class of the anti-4-1BB antibody of the present invention can be converted by known methods. For example, the class of the initial IgG antibody of the present invention can be converted to the IgM antibody of the present invention. Note that the IgG subclass can be converted to another subclass by class conversion technology, for example, IgG1 can be converted to IgG2. Therefore, the effector function of the antibody of the present invention can be converted to, for example, an IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM antibody by isotype switching for various therapeutic applications. In some embodiments, the antibody of the present invention is IgG4 antibody An antibody belongs to a particular isotype if its amino acid sequence is most similar to that of other isotypes.

[0068] In some embodiments, the antibodies of the invention are full-length antibodies, preferably IgG antibodies, hi other embodiments, the antibodies of the invention are antibody-antigen binding fragments or single chain antibodies.

[0069] In some embodiments, the anti-4-1BB antibody is a monovalent antibody, preferably a monovalent antibody having a deletion in the hinge region as described in WO2007059782 (incorporated herein by reference in its entirety). Thus, in some embodiments, the antibody is a monovalent antibody, wherein the anti-4-1BB antibody is constructed by the following method: i) providing a nucleic acid construct encoding the light chain of the monovalent antibody, the construct comprising a nucleotide sequence encoding the VL region of a selected antigen-specific anti-4-1BB antibody and a nucleotide sequence encoding the constant CL region of an Ig, wherein the nucleotide sequence encoding the VL region of the selected antigen-specific antibody and the nucleotide sequence encoding the CL region of the Ig are operatively linked, and in the case of the IgG1 subclass, the nucleotide sequence encoding the CL region has already been modified so that, in the presence of polyclonal human IgG or when administered to an animal or human, the CL region does not contain any amino acids that can form disulfide bonds or covalent bonds with other peptides comprising the identical amino acid sequence of the CL region; ii) providing a nucleic acid construct encoding the heavy chain of the monovalent antibody, the construct comprising a nucleotide sequence encoding the heavy chain of the selected antigen-specific anti-4-1BB antibody and a nucleotide sequence encoding the constant CL region of an Ig, wherein the nucleotide sequence encoding the VL region of the selected antigen-specific antibody and the nucleotide sequence encoding the CL region of the Ig are operatively linked, and in the case of the IgG1 subclass, the nucleotide sequence encoding the CL region has already been modified so that the CL region does not contain any amino acids that can form disulfide bonds or covalent bonds with other peptides comprising the identical amino acid sequence of the CL region; the nucleotide sequence encoding the VH region of an antibody and the nucleotide sequence encoding the constant CH region of a human Ig, wherein the nucleotide sequence encoding the CH region has already been modified so that, when administered to an animal or a human in the presence of polyclonal human IgG or to an animal or a human, the region corresponding to the hinge region and other regions of the CH region (e.g., the CH3 region) (e.g., required for an Ig subclass) do not contain any amino acid residues involved in forming disulfide bonds or covalent or stable non-covalent inter-heavy chain bonds with another peptide containing the identical amino acid sequence of the CH region of a human Ig, wherein the nucleotide sequence encoding the VH region of a selected antigen-specific antibody and the nucleotide sequence encoding the CH region of the Ig are operatively linked; iii) providing a cell expression system for producing a monovalent antibody; and iv) co-expressing the nucleic acid constructs of (i) and (ii) in cells of the cell expression system of (iii) to produce the monovalent antibody.

[0070] Similarly, in some embodiments, the anti-4-1BB antibody is a monovalent antibody, (i) a variable region or an antigen-binding portion of said domain of an antibody of the invention as described herein; (ii) a CH region of an immunoglobulin or a domain comprising the CH2 and CH3 domains thereof; Here, this CH region or a domain thereof has already been modified so that the hinge region and (if this immunoglobulin is not of the IgG4 subclass) the domain corresponding to another domain of the CH region (e.g., the CH3 domain) do not contain any amino acid residues that can form disulfide bonds with the same CH region or other covalent or stable non-covalent inter-heavy chain bonds with the same CH region in the presence of polyclonal human IgG.

[0071] In some other embodiments, the heavy chain of the monovalent antibody is modified to delete the entire hinge region.

[0072] In other embodiments, the sequence of the monovalent antibody is modified so that it does not contain any acceptor sites for N-linked glycosylation.

[0073] The present invention further includes "bispecific antibodies," in which the anti-4-1BB binding region (e.g., the 4-1BB binding region of an anti-4-1BB monoclonal antibody) is part of a bivalent or multivalent bispecific framework targeting one or more epitopes (e.g., the second epitope can include an epitope of an active transport receptor, thereby providing the bispecific antibody with improved cell translocation across biological barriers (e.g., the blood-brain barrier), or the second epitope is an epitope targeting another protein of interest). Thus, in another embodiment, a monovalent Fab of an anti-4-1BB antibody can be linked to a Fab or scfv targeting another, different protein to produce a bispecific antibody. Bispecific antibodies can have dual functions, for example, a therapeutic function conferred by the anti-4-1BB binding region and an enhanced transport function across biological barriers (e.g., the blood-brain barrier) by binding to a receptor molecule.

[0074] The antibodies and antigen-binding fragments thereof of the present invention further include single-chain antibodies. Single-chain antibodies are peptides in which the Fv domains of heavy and light chains are linked. In some embodiments, the present invention provides single-chain Fvs (scFvs), in which the heavy and light chains in the Fv of an anti-4-1BB antibody of the present invention are linked by a flexible peptide (typically about 10, 12, 15 or more amino acid residues) to form a single peptide chain. Methods for producing such antibodies are described, for example, in US 4,946,778; Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore ed., Springer-Verlag, New York, pages: 269-315 (1994); Bird et al., Science, 242, 423-426 (1988); Huston et al., PNAS USA 85, 5879-5883 (1988) and McCafferty et al., Nature, 348, 552-554 (1990). Single-chain antibodies are monovalent if only a single VH and VL are used, bivalent if two VH and VL are used, or multivalent if two or more VH and VL are used.

[0075] Antibodies of the present invention can be produced by any technique known in the art, including, but not limited to, any chemical, biological, genetic, or enzymatic technique, which may be used alone or in combination. Typically, the amino acid sequence of the desired sequence is known, and one of skill in the art can readily produce the antibody using standard techniques for producing polypeptides. For example, these antibodies can be synthesized by known solid-phase methods, preferably using commercially available peptide synthesizers (e.g., those manufactured by Applied Biosystems, Foster City, California) according to the manufacturer's instructions. Alternatively, antibodies of the present invention can be synthesized by recombinant DNA techniques known in the art. For example, a DNA sequence encoding the antibody can be incorporated into an expression vector and the vector introduced into a suitable eukaryotic or prokaryotic host for expression of the desired antibody, resulting in the antibody as a DNA expression product, which can then be isolated from the host using known techniques.

[0076] The antibodies and antigen-binding fragments thereof of the present invention can be modified by including any "suitable" number of modified amino acids and / or by coupling with coupling substituents. In such cases, "suitable" is typically determined by the ability to at least essentially retain 4-1BB selectivity and / or specificity associated with the underivatized parent anti-4-1BB antibody. The inclusion of one or more modified amino acids can contribute, for example, to an increase in polypeptide serum half-life, a decrease in polypeptide antigenicity, or improved polypeptide storage stability. Modifications to one or more amino acids can be made, for example, co-translationally during recombinant production, post-translationally (e.g., N-linked glycosylation at NXS / T sequences during mammalian cell expression), or by synthetic means. Non-limiting examples of modified amino acids include glycosylated amino acids, sulfated amino acids, isoprenylated (e.g., farnesylated, geranyl-geranylated) amino acids, acetylated amino acids, acylated amino acids, pegylated amino acids, biotin-acylated amino acids, carboxylated amino acids, phosphorylated amino acids, and the like. References for making amino acid modifications are well known in the art, see, for example, Walker, (1998), Protein Protocols On CD-Rom, Humana Press, Totowa, New Jersey. Modified amino acids may be selected from, for example, glycosylated amino acids, pegylated amino acids, farnesylated amino acids, acetylated amino acids, biotin-acylated amino acids, amino acids conjugated to a lipid moiety, or amino acids conjugated to an organic derivatizing agent.

[0077] The antibodies and antigen-binding fragments thereof of the present invention can also be chemically modified by covalent conjugation to a polymer to increase their circulating half-life. Exemplary polymers and methods for linking them to peptides are described in, e.g., U.S. Pat. Nos. 4,766,106, 4,179,337, 4,495,285, and 4,609,546. Exemplary polymers include polyoxyethylated polyols and polyethylene glycol (PEG) (e.g., PEG having a molecular weight of about 1,000-40,000 D, e.g., about 2,000-20,000 D, e.g., about 3,000-12,000 D).

[0078] The present invention further relates to fusion proteins comprising an antibody (preferably a monoclonal antibody) of the present invention.

[0079] The term "subject" refers to a warm-blooded animal, preferably a mammal (human, domestic and farm animals, zoo animals, sporting or pet animals, such as dogs, cats, cows, horses, sheep, pigs, goats, rabbits, etc.), more preferably a human. In one embodiment, the subject may be a "patient," i.e., a warm-blooded animal, more preferably a human, awaiting admission, receiving medical care, or the subject of a medical program or disease progression monitoring. In one embodiment, the subject is an adult (e.g., a subject 18 years of age or older). In another embodiment, the subject is a child (e.g., a subject under 18 years of age). In one embodiment, the subject is male. In another embodiment, the subject is female.

[0080] In one embodiment of the present invention, the sample is a biological sample, examples of which include, but are not limited to, diseased tissues and body fluids, preferably blood, more preferably serum, plasma, synovial fluid, bronchoalveolar lavage fluid, sputum, lymph, ascites, urine, amniotic fluid, peritoneal fluid, cerebrospinal fluid, pleural fluid, pericardial effusion, and tissue digests and extracts prepared from alveolar macrophages.

[0081] In one embodiment of the present invention, the term "sample" refers to a sample taken from an individual prior to any analysis.

[0082] Thus, in some embodiments, anti-4-1BB antibodies and antigen-binding fragments thereof of the present invention include whole antibodies, such as IgG (subclasses IgG1, IgG2, IgG3, and IgG4), IgA (subclasses IgA1 and IgA2), IgD, IgM, and IgE; antigen-binding fragments, such as SDRs, CDRs, Fvs, dAbs, Fabs, Fab2, Fab', F(ab')2, Fds, scFvs, camelids, or nanobodies; and variant sequences of antibodies or antigen-binding fragments thereof, such as variant sequences having at least 80% sequence identity to the above-mentioned antibodies or antigen-binding fragments thereof. In some embodiments, the present invention further includes derivatives comprising anti-4-1BB or antigen-binding fragments thereof, such as chimeric antibodies derived from the whole antibodies, humanized antibodies, fully human antibodies, recombinant antibodies, bispecific antibodies, products containing modified amino acids, products conjugated to polymers, products containing radioactive labels, products containing fluorescent labels, products containing enzyme-labeled substances, products containing chemiluminescent substances, and products containing paramagnetic labels.

[0083] In another aspect, the present invention relates to expression vectors encoding one or more polypeptide chains of an antibody or antigen-binding fragment thereof of the invention, which can be used to recombinantly produce the antibody and antigen-binding fragment thereof of the invention.

[0084] In the present invention, the expression vector may be any suitable DNA or RNA vector, including chromosomal vectors, non-chromosomal vectors, and synthetic nucleic acid vectors (containing a set of appropriate nucleic acid sequences for expression control elements). Examples of such vectors include derivatives of SV40, bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral nucleic acid (RNA or DNA) vectors. In some embodiments, the nucleic acid encoding the anti-4-1BB antibody is contained in a naked DNA or RNA vector, such as a linear expression element (e.g., as described in Sykes and Johnston, Nat Biotech, 12, 355-59 (1997)), a small nucleic acid vector (e.g., as described in US 6,077,835 and / or WO 00 / 70087), a plasmid vector (e.g., pBR322, pUC19 / 18, or pUC118 / 119), a minimal size nucleic acid vector (e.g., as described in Schakowski et al., Mol Ther, 3, 793-800 (2001)), or a precipitated nucleic acid vector construct, such as a CaPO4 precipitated construct (e.g., as described in WO 00 / 46147; Benvenisty and Reshef, PNAS USA 83, 9551-55 (1986); Wigler et al., Cell, 14, 725 (1978) and Coraro and Pearson, Somatic Cell Genetics, 2,603 ​​(1981). Such nucleic acid vectors and their uses are well known in the art (see, e.g., US Pat. Nos. 5,589,466 and 5,973,972). In some embodiments, the expression vector is X0GC (derived from patent WO2008 / 048037), pCDNA3.1 (ThermoFisher, catalog number V79520), or pCHO1.0 (ThermoFisher, catalog number R80007).

[0085] In some embodiments, the vector is suitable for expressing an anti-4-1BB antibody or an antigen-binding fragment thereof in bacterial cells. Examples of such vectors include BlueScript (Stratagene), pIN vectors (Van Heeke & Schuster, J. Biol. Chem., 264, 5503-5509 (1989)), and pET vectors (Novagen, Madison, Wisconsin).

[0086] The expression vector may be a vector suitable for expression in a yeast system. Any vector suitable for expression in a yeast system may be employed. Suitable vectors include, for example, vectors containing constitutive or inducible promoters (e.g., α-factor, alcohol oxidase, and PGH) (for reviews, see F. Ausubel et al., ed., Current Protocols in Molecular Biology, Greene Publishing and Wiley InterScience, New York (1987); Grant et al., Methods in Enzymol, 153, 516-544 (1987); Mattanovich, D. et al., Methods in Enzymol, 153, 516-544 (1987)). Mol. Biol., 824, 329-358 (2012); Celik, E. et al., Biotechnol. Adv., 30(5), 1108-1118 (2012); Li, P. et al., Appl. Biochem. Biotechnol., 142(2), 105-124 (2007); Boer, E. et al., Appl. Microbiol. Biotechnol., 77(3), 513-523 (2007); van der Vaart, JM, Methods Mol. Biol., 178, 359-366 (2002) and Holliger, P., Methods Mol. Biol., 178, 349-357 (2002).

[0087] In the expression vectors of the present invention, the nucleic acid encoding the anti-4-1BB antibody can contain any suitable promoter, enhancer, and other expression-contributing elements, or a combination thereof. Examples of such elements include a strong expression promoter (e.g., the human CMV IE promoter / enhancer and the RSV, SV40, SL3-3, MMTV, and HIV LTR promoters), an effective poly(A) terminator sequence, an origin of replication for producing the plasmid in E. coli, an antibiotic resistance gene as a selectable marker, and / or a convenient cloning site (e.g., a polylinker). The nucleic acid can also contain an inducible promoter for a constitutive promoter (e.g., CMV IE).

[0088] In another aspect, the present invention relates to recombinant eukaryotic or prokaryotic host cells (e.g., transfectomas) that produce the antibodies or antigen-binding fragments thereof of the invention, or the bispecific molecules of the invention. Exemplary host cells include yeast, bacteria, and mammalian cells (e.g., CHO or HEK cells). For example, in some embodiments, the present invention provides cells that contain a nucleic acid stably integrated into the cellular genome, the genome comprising a nucleic acid sequence encoding an anti-4-1BB antibody or antigen-binding fragment thereof of the invention. In other embodiments, the present invention provides cells that contain a non-integrated nucleic acid (e.g., a plasmid, cosmid, phagemid, or linear expression element), the nucleic acid comprising a sequence encoding an anti-4-1BB antibody or antigen-binding fragment thereof of the invention.

[0089] The antibodies and antigen-binding fragments thereof of the present invention can be produced in different cell lines, such as human cell lines, non-human mammalian cell lines, and insect cell lines, such as CHO cell lines, HEK cell lines, BHK-21 cell lines, murine cell lines (e.g., myeloma cell lines), fibrosarcoma cell lines, PER.C6 cell lines, HKB-11 cell lines, CAP cell lines, and HuH-7 human cell lines (Dumont et al., 2015, Crit Rev Biotechnol., Sep. 18, 1-13, the contents of which are incorporated herein by reference).

[0090] Antibodies of the invention and culture medium are suitably isolated by conventional immunoglobulin purification methods, such as protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0091] The present invention further relates to compositions comprising, consisting of or consisting essentially of an antibody of the invention.

[0092] As used herein, with respect to a composition, "consisting essentially of" means that at least one antibody of the invention, as described above, is the only biologically active therapeutic agent or reagent in the composition.

[0093] In one embodiment, the composition of the present invention is a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier.

[0094] The term "pharmaceutically acceptable carrier" refers to an excipient that does not produce any adverse, allergic, or other untoward reaction when administered to animals, preferably humans. It includes any and all solvents, dispersion media, coating layers, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. For human administration, formulations should meet sterility, pyrogenicity, general safety and purity standards required by regulatory agencies (e.g., FDA office and EMA).

[0095] The present invention further relates to a medicament comprising, consisting of or consisting essentially of an antibody of the invention.

[0096] In some embodiments, the glycosylation of the antibodies of the invention is modified. For example, an aglycosylated antibody (i.e., the antibody is not glycosylated) can be produced. Altering glycosylation can, for example, increase the affinity of the antibody for an antigen or alter the ADCC activity of the antibody. Such carbohydrate modifications can be achieved, for example, by altering one or more glycosylation sites within the antibody sequence. For example, one or more amino acid substitutions can be made to eliminate one or more variable region framework glycosylation sites, thereby eliminating glycosylation at those sites. Such aglycosylation can improve the affinity of the antibody for an antigen. U.S. Patent Nos. 5,714,350 and 6,350,861 to Co et al. (incorporated herein by reference) describe such methods in more detail. Alternatively, antibodies with an altered type of glycosylation can be produced, such as hypofucosylated or nonfucosylated antibodies with reduced amounts or no fucosyl residues, or antibodies with added bisecting GlcNac structures. Such an altered fucosylation mode has been shown to improve the ADCC ability of antibodies. Such carbohydrate modifications may be achieved, for example, by expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and may be used as host cells to produce antibodies with altered glycosylation by expressing a recombinant antibody of the invention in the host cell. For example, Hang et al., in EP 1176195 (incorporated herein by reference), describe a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyltransferase, such that antibodies expressed in such a cell line exhibit hypofucosylation or an absence of fucosyl residues.Thus, in some embodiments, human antibodies (preferably monoclonal antibodies) of the invention may be produced by recombinant expression in a cell line exhibiting a hypofucosylated or nonfucosylated mode, e.g., a mammalian cell line lacking expression of the FUT8 gene encoding fucosyltransferase. Presta's PCT disclosure WO 03 / 035835 (incorporated herein by reference) describes a mutant CHO cell line, Lecl3 cells, which have a reduced ability to attach fucose to Asn(297)-linked carbohydrates, resulting in hypofucosylation of antibodies expressed in these host cells (see also Shields, R.L. et al., 2002 J. Biol. Chem. 277:26733-26740). Umana et al., PCT Publication WO 99 / 54342 (incorporated herein by reference), describes an engineered cell line that expresses a glycoprotein-modified glycosyltransferase (e.g., β(1,4)-N-acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in the engineered cell line display an added bisecting GlcNac structure, resulting in improved ADCC activity of the antibody (see also Umana et al., 1999 Nat. Biotech. 17:176-180). Eureka Therapeutics further described engineered CHO mammalian cells capable of producing antibodies with an altered mammalian glycosylation mode lacking fucose residues (http: / / www.eurekainc.com / a&boutus / companyoverview.html). Alternatively, the human antibodies (preferably monoclonal antibodies) of the present invention can be produced in yeast or filamentous fungi, which are used in a mammalian-like glycosylation mode and can produce antibodies lacking fucose as a glycosylation mode (see, e.g., EP1297172B1).

[0097] 4-1BB (CD137 / TNFRSF9) is expressed on antigen-activated T cells but not on resting T cells. It is also known to be expressed on dendritic cells (DCs), natural killer cells (NKs), activated CD4+ and CD8+ T lymphocytes, eosinophils, natural killer T cells (NKT), and mast cells, but not on the surface of myeloid-derived suppressor cells (MDSCs). Anti-4-1BB antibodies have the ability to activate cytotoxic T cells and enhance the production of gamma interferon (IFN-γ). The tumor necrosis factor receptor superfamily (TNFRSF) is a protein superfamily consisting of 29 members that plays an important role in the human immune system. This molecular family is divided into two types: death receptors (8 members) and activating receptors. Each contains an intracellular signaling pathway activation domain and an extracellular receptor site. These receptor sites can be activated by binding to the corresponding tumor necrosis factor superfamily (TNFSF) ligand.

[0098] The TNFSF-TNFRSF ligand-receptor (e.g., CD40-CD40L, CD27-CD70, or OX40-OX40L) signaling pathway can regulate many important processes in vivo, such as cell development and death, and the induction of cytokines and chemokines. Increasing evidence has demonstrated that TNFRSF and TNFSF members are involved in inflammation and pathology in various diseases, including cancer. In immunotherapy, effective immune responses require two types of signals to fully activate T cells and other immune cells. The first type of signal, i.e., antigen-specific signal, is generated by the interaction between lymphocyte receptors and specific peptides bound by major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs). The second type is antigen-nonspecific costimulatory signal. Such signals are provided by the interaction between T cells and costimulatory molecules expressed on APCs. 4-1BB is a costimulatory molecule and belongs to the TNFRSF. It was discovered in the late 1980s during a T cytokine screening study, in which mouse helper T cells and cytotoxic T cells were stimulated with concanavalin A. Human 4-1BBL was first isolated in 1994 from CD4+ T lymphocytes activated by a direct expression clone. 4-1BBL is primarily expressed on dendritic cells, B cells, or macrophages.

[0099] The antibodies of the present invention act on 4-1BB, a potent T cell-specific costimulatory molecule that is also expressed on many non-T cells, such as DCs, monocytes, B cells, mast cells, NK cells, and neutrophils. Activation of the 4-1BB costimulatory signal by anti-4-1BB agonists or 4-1BBL transfection can induce cell proliferation, cytokine expression, bactericidal activity, and support for T cell effector function. Binding of agonist antibodies to 4-1BB can enhance the immune killing function of T cells. Simultaneously, it can induce immune cell activation and promote cytokine (e.g., IL-8) secretion.

[0100] The anti-human 4-1BB chimeric monoclonal antibody provided by the present invention can bind to human 4-1BB and cynomolgus monkey 4-1BB with similar affinity, but does not bind to mouse 4-1BB, demonstrating species specificity. The anti-human 4-1BB chimeric monoclonal antibody has strong binding specificity, binding only to 4-1BB, but not to B7 family members, CD28 family members, or CTLA-4, LAG-3, TIM-3, OX40, or CD27 proteins. The results are shown in Figure 3.

[0101] Where ranges of values ​​are provided, unless otherwise stated herein, it is to be understood that each intervening value, tenth of a unit up to the lower limit, between the upper and lower limits of this range, and any other such value or intervening value within any said range, is included within the scope of the invention. Except as specifically excluded limits, the upper and lower limits of these smaller ranges, which may independently be included in smaller ranges, are also included within the invention, provided that they exclude any specifically excluded boundary within the range. Where a range includes one or two limits, ranges excluding one or both included boundaries are also included within the invention.

[0102] Unless otherwise defined, all technical or scientific terms used herein shall have the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the presently preferred methods and materials are disclosed. All publications mentioned herein are incorporated by reference in their entirety.

[0103] Hereinafter, embodiments of the present invention will be described in detail with reference to examples. However, those skilled in the art will understand that the following examples are merely for the purpose of illustrating the present invention and should not be construed as limiting the scope of the present invention. Meanwhile, the examples provided herein are intended to illustrate the manufacturing process of the antibody of the present invention. This manufacturing process is merely intended to illustrate related methods and is not limiting. Those skilled in the art will recognize that various modifications can be made to the present invention without departing from the spirit of the present invention. Such modifications are also within the scope of the present invention. Meanwhile, the examples provided herein are intended to illustrate the features and advantages of the antibody of the present invention, but the present invention is not limited to these features and advantages.

[0104] Unless otherwise specified, the following experimental methods are all conventional methods, and unless specific conditions are specified, they are performed according to conventional conditions or conditions recommended by the manufacturer. Unless otherwise specified, the experimental materials used are readily available from commercial companies. The antibodies used in the following examples of the present invention are all commercially available standard antibodies. [Example]

[0105] Example 1: Production of mouse-derived anti-human 4-1BB monoclonal antibody 1.1 Animal Immunization Experimental animals were 6-8 week-old female BALB / c mice (purchased from Beijing Weitong Lihua). After one week of adaptation, the mice were subjected to immunization. For the first immunization, 50 μg of recombinant human 4-1BB-Fc protein (Beijing Sino Biological Co., Ltd., catalog number 10041-H03H) and Freund's complete adjuvant (Sigma-Aldrich, catalog number F5881) were thoroughly mixed to form an emulsion and administered intraperitoneally to the mice. Two weeks later, booster immunizations were performed. For the second immunization, 25 μg of recombinant human 4-1BB-Fc protein and Freund's incomplete adjuvant (Sigma-Aldrich, catalog number F5806) were mixed to form an emulsion and administered intraperitoneally to the mice. Booster immunizations were performed every two weeks using the same method, for a total of three times. Ten days after the final immunization, blood was collected from the retro-orbital venous plexus of the mice, and serum was separated by centrifugation. Antibody titers were measured using enzyme-linked immunosorbent assay (ELISA) with recombinant human 4-1BB-His protein (Beijing Sino Biological Co., Ltd., catalog number 10041-H08H). Mice with high antibody titers were selected and fused to produce hybridomas. Three days before fusion, 50 μg of adjuvant-free recombinant human 4-1BB-His protein was intraperitoneally administered. On the day of fusion, spleens were aseptically removed and single spleen cell suspensions were prepared in DMEM medium (Gibco, catalog number 11965) to prepare for fusion.

[0106] 1.2. Preparation of hybridoma cells SP2 / 0 myeloma cells (purchased from the Chinese Academy of Sciences) in the logarithmic growth phase were harvested and centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded, and the cells were suspended in incomplete DMEM medium and counted. The required number of cells and spleen cells were mixed in a 50 mL centrifuge tube at the specified ratio and centrifuged for 5 minutes. The supernatant was discarded, and the bottom of the centrifuge tube was gently tapped with the palm of the hand to loosen and homogenize the precipitated cells. 1 mL of PEG (Sigma, catalog number P7181) was gradually added over 1 minute and allowed to stand for 90 seconds. Fusion was stopped by adding incomplete DMEM medium to the 50 mL volume, allowing to stand for 5 minutes, then centrifuged at 1000 rpm for 5 minutes and the supernatant was discarded. 20 mL of HAT medium (Sigma, catalog number H0262-10VL) was added, and the fused cells were gently dispersed by blowing, resulting in a cell count of 1 × 10 cells. 5 The hybridoma cells were seeded at 1000 cells / well in HAT medium and incubated in a 37°C, 5% CO2 incubator. After 7-10 days, the HAT medium was replaced with HT medium (Sigma, catalog number H0137-10VL). The hybridoma cell growth was monitored periodically, and when the cells reached more than 1 / 10 of the well's surface area, the supernatant was aspirated and subjected to antibody detection. Positive clones were expanded and cryopreserved.

[0107] 1.3. Screening and identification of clones Anti-human 4-1BB antibodies were screened in hybridoma culture supernatants by enzyme-linked immunosorbent assay (ELISA). Recombinant human 4-1BB (Beijing Sino Biological Co., Ltd., catalog number 10041-H08H) was coated onto a 96-well high-binding ELISA plate at a coating concentration of 1 μg / mL in a coating volume of 100 μL / well using carbonate buffer solution, pH 9.6. Coating was performed overnight at 4°C. The plate was washed five times with PBST buffer. Blocking was performed with 300 μL / well of PBST buffer containing 1% bovine serum albumin (BSA) and incubated for 1 hour at 25°C. The plate was washed five times with PBST buffer. Culture supernatant samples and positive serum controls were added at 100 μL / well and incubated for 1 hour at 25°C. The plate was washed five times with PBST buffer. Next, 100 μL / well of horseradish peroxidase-conjugated anti-mouse IgG antibody (Abcam, catalog no. Ab7068) diluted 1:10,000 in PBST buffer containing 1% BSA was added and incubated at 25°C for 1 hour. The plate was washed five times with PBST buffer. 100 μL / well of the color-developing substrate TMB was added and allowed to develop at room temperature for 10 minutes. 100 μL / well of 1M H2SO4 was added to stop the color development. The absorbance at 450 nm was read using a microplate reader. Positive clones capable of secreting anti-human 4-1BB selective antibodies were selected based on the intensity of OD450 nm.

[0108] After agonist antibodies bind to 4-1BB, they can enhance the immune killing function of T cells. At the same time, they can induce immune cell activation and promote the secretion of cytokines (e.g., IL-8). Agonist anti-human 4-1BB antibodies were screened based on GS-H2 / 4-1BB cell experiments. Hybridoma cells from positive clones were inoculated intraperitoneally into mice. One week later, ascites was extracted and purified to obtain antibody protein. GS-H2 / 4-1BB cells were then incubated. On the day of screening, GS-H2 / 4-1BB cells were digested with trypsin, stopped digestion with complete medium, centrifuged at 1000 rpm for 5 minutes, the supernatant was discarded, and the cells were resuspended in MEM medium containing 2% serum (Gibco, catalog number 10370-021) at 1 x 10 5 The cells were resuspended at a cell density of 100 μL / well and plated in a 96-well plate. The plate was incubated for 2 hours in a 37°C, 5% CO2 incubator. Biotin-labeled anti-mouse IgG antibody (Nakasugi Kinbashi, catalog number ZB-2020) and Dynabeads streptavidin magnetic beads M-280 (Invitrogen, catalog number 112-05D) were incubated at room temperature for 30 minutes. The magnetic beads were isolated with a magnet for 2–3 minutes and washed 4–5 times with PBS. After the 2-hour incubation, 50 μL of the test antibody (final concentration: 10 μg / mL) and 50 μL of the incubated magnetic beads (final concentration: 100 μg / mL) were added to each well of the cell plate. The plate was then incubated for 24 hours in a 37°C, 5% CO2 incubator. The expression level of IL-8 in the supernatant of GS-H2 / 4-1BB cells was detected using an IL-8 detection kit (Daco-Wei, catalog number 1110802) according to the manufacturer's instructions, and positive clones capable of secreting anti-human 4-1BB agonist antibodies were selected based on the OD450nm intensity.

[0109] The results are shown in Table 1 and Figure 1A. Antibodies secreted from multiple anti-human 4-1BB clones had 4-1BB binding activity. The results are shown in Figure 1B. Antibodies secreted from multiple anti-human 4-1BB clones had 4-1BB agonist activity.

[0110] [Table 5]

[0111] 1.4. Measurement of monoclonal antibody sequences Clones obtained through screening that possessed both antigen-binding and agonistic activity were subjected to antibody DNA sequencing. Cellular mRNA was extracted using the RNAprep Pure Kit (Tiangen, DP419). Total RNA extracted from the hybridoma was then reverse transcribed using the SMART 5'RACE Kit (Clontech, Catalog No. 634849) to synthesize the first strand of human 4-1BB cDNA. Primers VHGSP (SEQ ID NO. 32) and VLGSP (SEQ ID NO. 33) for PCR amplification were designed. The target bands obtained through PCR amplification were cloned into a linearized pRACE vector (Clontech, Catalog No. 634859) using the in-fusion method. Monoclonal antibodies were selected and subjected to DNA sequencing.

[0112] Example 2: Preparation of chimeric anti-human 4-1BB monoclonal antibody The antibody light chain variable region sequence obtained by PCR amplification of the 4-1BB-246-8-33-83 clone is shown in SEQ ID NO. 7, and the antibody heavy chain variable region sequence is shown in SEQ ID NO. 8. The complementarity-determining region sequences can be obtained by eliminating the framework region sequences based on the mouse variable region sequence. Here, the amino acid sequences of the three light chain complementarity-determining regions, LCDR1, LCDR2, and LCDR3, are shown in SEQ ID NOs. 1, 2, and 3, respectively. The amino acid sequences of the three heavy chain complementarity-determining regions, HCDR1, HCDR2, and HCDR3, are shown in SEQ ID NOs. 4, 5, and 6, respectively. The chimeric 4-1BB monoclonal antibody constructed from the 4-1BB-246-8-33-83 clone was named mAb-33-83. The light chain of the chimeric monoclonal antibody mAb-33-83 was a combination of the light chain variable region (sequence shown in SEQ ID NO. 7) and light chain constant region (sequence shown in SEQ ID NO. 9) of the 4-1BB-246-8-33-83 clone, and the heavy chain of the mAb-33-83 antibody was a combination of the heavy chain variable region (sequence shown in SEQ ID NO. 8) and heavy chain constant region (sequence shown in SEQ ID NO. 10). The amino acid sequences encoding the light and heavy chains of the above antibodies were synthesized by gene synthesis (completed by Suzhou King Weizhi Biotechnology Co., Ltd.) to obtain the corresponding nucleotide sequences, which were then cloned into the eukaryotic expression vector X0GC. The recombinant expression vector was then transfected into the ExpiCHO cell line (ExpiCHOTM, Catalog No. A29133, Invitrogen). The day before transfection, the cells were seeded and transferred to fresh ExpiCHOTM Expression Medium (ExpiCHOTM Expression Medium, Catalog No. A29100, Invitrogen) at a concentration of 35 × 10 5 Resuspend the cells at a cell density of 70-200 x 10 cells / mL and count on the day of transfection. 5 Dilute cells in pre-warmed ExpiCHOTM Expression Medium to a final density of 60 x 10 cells / mL. Viability should be greater than 95%. 5Mix the plasmids and transfection reagent ExpiFectamine in OptiPRO™ medium (Cat. No. 12309, Invitrogen) according to the transfection volume of cells / mL. TM The CHO reagent (catalog no. A29131, Invitrogen) was diluted to a final plasmid concentration of 0.5 μg / mL. The diluted transfection reagent was gently added to the plasmid and allowed to stand for 1-5 minutes. The plasmid transfection reagent compound was then added to the cells, and the cells were incubated in a cell incubator at 125 rpm, 37°C, and 8% CO2. The day after transfection, ExpiFectamine® CHO Enhancer (catalog no. A29131, Invitrogen) and ExpiCHO® Feed (catalog no. A29101-02, Invitrogen) were added, and the cell incubator was adjusted to a 125 rpm shaker, 32°C, and 5% CO2. The supernatant of the 10-day transfected cell culture was collected by centrifugation.

[0113] Example 3 Binding activity of chimeric anti-human 4-1BB monoclonal antibody to human 4-1BB The binding ability of the chimeric anti-human 4-1BB monoclonal antibody to human 4-1BB was measured by enzyme-linked immunosorbent assay (ELISA). The specific procedure was as follows: Recombinant human 4-1BB (Beijing Sino Biological Co., Ltd., catalog number 10041-H08H) was coated onto a 96-well high-adsorption ELISA plate at a coating concentration of 1 μg / mL in a coating volume of 100 μL / well using carbonate buffer solution at pH 9.6. The coating was performed overnight at 4°C. The plate was washed five times with PBST buffer. The plate was blocked with 300 μL / well of PBST buffer containing 1% BSA and incubated at 25°C for 1 hour. The plate was washed five times with PBST buffer. Anti-human 4-1BB antibody samples and the control urelumab (derived from patent sequence WO2004010947) were added at 100 μL / well and incubated at 25°C for 1 hour. The plate was washed five times with PBST buffer. Next, 100 μL / well of horseradish peroxidase-conjugated anti-mouse IgG antibody (Abcam, Cat. No. Ab7068) diluted 1:10,000 in PBST buffer containing 1% BSA was added and incubated at 25°C for 1 hour. The plate was washed five times with PBST buffer. 100 μL / well of the color-developing substrate TMB was added and allowed to develop at room temperature for 10 minutes. Color development was stopped by adding 100 μL / well of 1 M H2SO4. The absorbance at 450 nm was read using a microplate reader.

[0114] The results are shown in Figure 2. The anti-human 4-1BB chimeric monoclonal antibody mAb-33-83 had excellent binding affinity to human 4-1BB, and the binding activity was equivalent to that of the control, Urelumab.

[0115] Example 4 Species specificity and binding specificity of chimeric anti-human 4-1BB monoclonal antibody The species specificity of the chimeric anti-human 4-1BB monoclonal antibody was measured by enzyme-linked immunosorbent assay (ELISA). The specific procedure was as follows: Recombinant human 4-1BB, cynomolgus monkey 4-1BB, and mouse 4-1BB (all purchased from Beijing Sino Biological Co., Ltd.) were coated onto a 96-well high-binding ELISA plate at a coating concentration of 1 μg / mL in a coating volume of 100 μL / well using carbonate buffer solution (pH 9.6). The coating was performed overnight at 4°C. The plate was washed five times with PBST buffer. Blocking was performed with 300 μL / well of PBST buffer containing 1% BSA and incubated for 1 hour at 25°C. The plate was washed five times with PBST buffer. Serially diluted anti-human 4-1BB chimeric monoclonal antibody samples in PBST buffer containing 1% BSA were added at 100 μL / well and incubated for 1 hour at 25°C. The plate was then washed five times with PBST buffer. Next, 100 μL / well of horseradish peroxidase-conjugated anti-human IgG antibody (Chemicon, Cat. No. AP309P) diluted 1:10,000 in PBST buffer containing 1% BSA was added and incubated at 25°C for 1 hour. The plate was washed five times with PBST buffer. 100 μL / well of the color-developing substrate TMB was added and allowed to develop at room temperature for 10 minutes. Color development was stopped by adding 100 μL / well of 1 M H2SO4. The absorbance at 450 nm was read using a microplate reader.

[0116] The binding specificity of the chimeric anti-human 4-1BB monoclonal antibody was measured by ELISA. The specific procedure was as follows: Recombinant human CD80, CD86, 4-1BB, PD-L2, B7-H2, CTLA4, PD-1, LAG-3, TIM-3, BTLA, CD28, 4-1BB, OX40, CD27, and ICOS were coated onto a 96-well high-binding ELISA plate using a carbonate buffer solution at pH 9.6. CD28 protein was purchased from Acro Biosystems Co., Ltd. (Beijing), and the remaining proteins were purchased from Sino Biological Co., Ltd. (Beijing). Coating was performed overnight at 4°C at a coating concentration of 1 μg / mL in a coating volume of 100 μL per well. The plate was then washed five times with PBST buffer. Blocking was performed with 300 μL per well of PBST buffer containing 1% BSA, followed by incubation at 25°C for 1 hour. The plate was then washed five times with PBST buffer. Serially diluted anti-human 4-1BB chimeric monoclonal antibody samples and control urelumab and isotype controls in PBST buffer containing 1% BSA were added at 100 μL / well and incubated at 25°C for 1 hour. The plates were washed five times with PBST buffer. Horseradish peroxidase-conjugated anti-human IgG antibody (Chemicon, catalog no. AP309P), diluted 1:10,000 in PBST buffer containing 1% BSA, was then added at 100 μL / well and incubated at 25°C for 1 hour. The plates were washed five times with PBST buffer. The color-developing substrate TMB was added at 100 μL / well and allowed to develop at room temperature for 10 minutes. The color development was stopped by adding 100 μL / well of 1 M H2SO4. The absorbance at 450 nm was read using a microplate reader.

[0117] As shown in Figure 3A, the anti-human 4-1BB chimeric monoclonal antibody mAb-33-83 can bind to human 4-1BB and cynomolgus monkey 4-1BB with similar affinity, but does not bind to mouse 4-1BB, demonstrating species specificity. As shown in Figure 3B, the anti-human 4-1BB chimeric monoclonal antibody mAb-33-83 has strong binding specificity, binding only to 4-1BB, but not to B7 family members, CD28 family members, or CTLA-4, LAG-3, TIM-3, OX40, or CD27 proteins.

[0118] Example 5 Blocking activity of chimeric anti-human 4-1BB monoclonal antibody against the binding of 4-1BB to its receptor The blocking activity of the chimeric anti-human 4-1BB monoclonal antibody mAb-33-83 on the binding of 4-1BB to its receptor was measured by enzyme-linked immunosorbent assay (ELISA). The specific procedure was as follows: Recombinant human 4-1BB (Beijing Sino Biological Co., Ltd., catalog number 10041-H08H) was coated onto a 96-well high-binding ELISA plate at a coating concentration of 1 μg / mL in a coating volume of 100 μL per well using carbonate buffer solution, pH 9.6. The coating was performed overnight at 4°C. The plate was washed five times with PBST buffer. The plate was blocked with 300 μL per well of PBST buffer containing 1% BSA and incubated at 25°C for 1 hour. The plate was then washed five times with PBST buffer. Anti-human 4-1BB antibody samples were added at 50 μL / well, and biotin-labeled 4-1BBL (Acro Biosystems, Beijing, Catalog No. 41L-H82F9) was added at 50 μL / well to a concentration of 200 ng / mL (final concentration: 100 ng / mL). The plate was incubated at 25°C for 90 minutes. The plate was washed five times with PBST buffer. Streptavidin-HRP (BD, Catalog No. 554066) diluted 1:1000 in PBST buffer containing 1% BSA was then added at 100 μL / well, and the plate was incubated at 25°C for 1 hour. The plate was washed five times with PBST buffer. The chromogenic substrate TMB was added at 100 μL / well, and the color was developed at room temperature for 10 minutes. The color development was stopped by adding 100 μL / well of 1 M H2SO4. The absorbance at 450 nm was read on a microplate reader.

[0119] The results are shown in Figure 4. The blocking activity of the anti-human 4-1BB chimeric monoclonal antibody against 4-1BB / 4-1BBL was superior to that of the control, Urelumab.

[0120] Example 6 Antitumor Pharmacodynamic Study of Chimeric Anti-Human 4-1BB Monoclonal Antibody Six- to eight-week-old female h4-1BB / h4-1BB double-humanized mice (mouse-derived 4-1BB and 4-1BB knockout, human-derived 4-1BB and 4-1BB overexpression, Jiangsu Biocytogen Co., Ltd.) were used as experimental materials. After allowing the mice to adapt to the environment for 1 week, 1 × 10 IgG was administered to each mouse. 6 MC38 / h4-1BB mouse colon tumor cells (MC38 purchased from Shanghai Shunran) were subcutaneously inoculated into the right dorsal region. The tumor volume was approximately 100 mm 3 When the tumor volume reached 100%, the tumor-bearing mice were divided into groups of six mice each based on tumor volume. The vehicle (DPBS, GIBCO, Cat. No. 14190-136), 35 nmol / kg of the anti-human 4-1BB chimeric monoclonal antibody mAb-33-83, or 35 nmol / kg of the control urelumab were administered intraperitoneally twice a week for two consecutive weeks. The tumor volume was measured twice a week from the day of administration, and its major axis (a) and minor axis (b) were measured. The formula for calculating tumor volume was: tumor volume (mm 3 )=(a×b 2 ) / 2. The duration of tumor volume measurement was 2 weeks, that is, 2 weeks after administration was stopped.

[0121] The results are shown in Figure 5. In the homologous tumor model, the anti-human 4-1BB chimeric monoclonal antibody mAb-33-83 had anti-tumor activity, significantly inhibiting tumor growth, and its effect was superior to that of the control, Urelumab.

[0122] Example 7 Production of humanized anti-human 4-1BB monoclonal antibody The humanized anti-human 4-1BB monoclonal antibody was obtained by the method of Leung et al. (1995, Molecule Immunol 32:1413-27). From the GermLine database, a humanization template that best matched the variable region sequence of the mouse-derived antibody was selected, where the light chain variable region template was hIGKV1-27*01+hIGKJ4. The heavy chain variable region template was hIGHV1-69*02+hIGHJ6*01. The light chain CDR region of the mouse-derived antibody was grafted into the selected humanization template, replacing the CDR region of the human template, to obtain the light chain variable region of the grafted humanized antibody, the sequence of which is shown in SEQ ID NO. 11. The heavy chain variable region sequence of the grafted humanized antibody is shown in SEQ ID NO. 12. Backmutation was performed at selected sites in SEQ ID NO. 11 and SEQ ID NO. 12. The resulting light chain variable region sequences are shown in SEQ ID NOs. 13-20, and the resulting heavy chain variable region sequences are shown in SEQ ID NOs. 21-31. The light chain variable regions were each linked to a light chain constant region (SEQ ID NO. 9) to obtain the corresponding full-length light chain sequences. The heavy chain variable regions were each linked to a heavy chain constant region (SEQ ID NO. 10) to obtain the corresponding full-length heavy chain sequences. Usable humanized sequences were obtained through affinity and stability screening. The sequence information for the light and heavy chain variable regions of the resulting humanized monoclonal antibodies is shown in Table 2, where the ID column represents the abbreviations for the resulting chimeric and humanized monoclonal antibodies, respectively.

[0123] [Table 6]

[0124] Example 8 Antigen-binding activity of humanized anti-human 4-1BB monoclonal antibody The humanized anti-4-1BB monoclonal antibody with ID number z0 obtained in Example 7 is designated BH3145b (sequence information: VH SEQ ID NO. 12; VL SEQ ID NO. 11). The antigen binding activity of the humanized anti-4-1BB monoclonal antibody BH3145b was detected using the same test procedures as in Example 4. The experimental results are shown in Figure 6. As can be seen from Figure 6, the humanized anti-4-1BB monoclonal antibody BH3145b has excellent binding affinity to human 4-1BB, and the binding activity is comparable to that of the anti-human 4-1BB chimeric monoclonal antibody mAb-33-83 and the control urelumab.

[0125] Example 9 Blocking activity of humanized anti-human 4-1BB monoclonal antibodies against the binding of 4-1BB to its receptor The humanized anti-4-1BB monoclonal antibody described in Example 7 is designated BH3145b. The blocking activity of the humanized anti-4-1BB monoclonal antibody against the binding of 4-1BB to its receptor was detected. The test procedures were the same as in Example 5, and the results are shown in Figure 7. As can be seen from Figure 7, the blocking activity of the humanized anti-4-1BB monoclonal antibody BH3145b against 4-1BB / 4-1BBL was slightly inferior to that of the anti-human 4-1BB chimeric monoclonal antibody mAb-33-83, but its blocking activity was superior to that of the control, Urelumab.

[0126] Finally, the above embodiments are intended to illustrate the technical solutions of the present invention, but are not intended to limit the same. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the technical solutions described in the above embodiments can still be modified or some or all of the technical features can be replaced with equivalents, and such modifications or replacements do not cause the essence of the corresponding technical solutions to depart from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An isolated anti-human 4-1BB antibody or antigen-binding fragment thereof, The light chain variable region comprises three complementarity determining regions (LCDRs) as set forth in SEQ ID NO. 7 and three complementarity determining regions (HCDRs) as set forth in SEQ ID NO. 8, The three complementarity determining regions (LCDRs) are LCDR1 shown in SEQ ID No. 1, LCDR2 shown in SEQ ID No. 2, and LCDR3 shown in SEQ ID No. 3; The three complementarity determining regions (HCDRs) are HCDR1 shown in SEQ ID No. 4, HCDR2 shown in SEQ ID No. 5, and HCDR3 shown in SEQ ID No. 6; An anti-human 4-1BB antibody or an antigen-binding fragment thereof.

2. The anti-human 4-1BB antibody or antigen-binding fragment thereof according to claim 1, wherein the anti-human 4-1BB antibody or antigen-binding fragment thereof is a chimeric antibody, a humanized antibody, or a fully humanized antibody.

3. the heavy chain constant region sequence of the antibody is selected from the constant region sequences of any of human IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, and / or the light chain constant region sequence of the antibody is selected from a κ chain or a λ chain; The anti-human 4-1BB antibody or antigen-binding fragment thereof according to claim 1 or 2.

4. The anti-human 4-1BB antibody or antigen-binding fragment thereof according to claim 3, wherein the heavy chain constant region sequence is selected from the constant region sequences of IgG1 or IgG4, and / or the light chain constant region sequence is selected from the constant region sequences of a light chain κ.

5. The anti-human 4-1BB antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the light chain variable region has the amino acid sequence shown in SEQ ID NO. 7 and the heavy chain variable region has the amino acid sequence shown in SEQ ID NO.

8.

6. (a) the light chain variable region has an amino acid sequence selected from the group consisting of SEQ ID NOs. 13-20; the heavy chain variable region has an amino acid sequence selected from SEQ ID NOs. 21-31; or (b) the light chain variable region has the amino acid sequence set forth in SEQ ID NO. 11; the heavy chain variable region has an amino acid sequence selected from SEQ ID NOs. 21-31; or (c) the light chain variable region has an amino acid sequence selected from the group consisting of SEQ ID NOs. 13-20; The anti-human 4-1BB antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the heavy chain variable region has the amino acid sequence shown in SEQ ID NO.

12.

7. The anti-human 4-1BB antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the light chain variable region has the amino acid sequence shown in SEQ ID NO. 11 and the heavy chain variable region has the amino acid sequence shown in SEQ ID NO.

12.

8. The antigen-binding fragment is F(ab') ２ , Fab', Fab, Fd, Fv, scFv, bispecific antibody, camel antibody, CDR, and the smallest antibody recognition unit (dAb), The anti-human 4-1BB antibody or antigen-binding fragment thereof according to any one of claims 1 to 7.

9. The antigen-binding fragments include Fab, F(ab') ２ The anti-human 4-1BB antibody or antigen-binding fragment thereof according to claim 8, which is an scFv or scFv.

10. (1) DNA or RNA encoding the anti-human 4-1BB antibody or antigen-binding fragment thereof according to any one of claims 1 to 9; or (2) A nucleic acid completely complementary to the nucleic acid defined in (1).

11. An expression vector comprising the nucleic acid molecules of claim 10 operatively ligated together.

12. A host cell comprising the nucleic acid molecule of claim 10 or the expression vector of claim 11.

13. A composition comprising an anti-human 4-1BB antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, a nucleic acid molecule according to claim 10, a vector according to claim 11, or a host cell according to claim 12, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

14. Culturing the host cell of claim 12 under culture conditions suitable for expression of the anti-human 4-1BB antibody or antigen-binding fragment thereof. A method for producing the anti-human 4-1BB antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.

15. After said culturing, isolating and purifying the resulting product.

15. The method of claim 14.

16. Use of the anti-human 4-1BB antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, the nucleic acid molecule according to claim 10, the vector according to claim 11, or the host cell according to claim 12 in the manufacture of a medicament for preventing and / or treating a 4-1BB-mediated disease or condition, The disease or condition is a tumor.

17. The use according to claim 16, wherein the tumor is one or more selected from leukemia, lymphoma, myeloma, brain tumor, squamous cell carcinoma of the head and neck, non-small cell lung cancer, nasopharyngeal carcinoma, esophageal cancer, gastric cancer, pancreatic adenocarcinoma, gallbladder cancer, liver cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, bladder cancer, renal cell carcinoma, and melanoma.

Images